Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: Comparison with the Na+ channel-mediated release

Neuropharmacology

Volumn 53, Issue 7, 2007, Pages 854-862

  Sitges, María ^a   Guarneros, Araceli ^a   Nekrassov, Vladimir ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Antiepileptic drugs; Cerebral presynaptic calcium channels; Epilepsy; Presynaptic sodium channels; Synaptosomes

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; GLUTAMIC ACID; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; SODIUM CHANNEL; SODIUM CHANNEL STIMULATING AGENT; TOPIRAMATE; TRITIUM; VALPROIC ACID; VERATRIDINE; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPILEPSY; EVOKED RESPONSE; EXCITATORY JUNCTION POTENTIAL; HIPPOCAMPUS; INHIBITION KINETICS; MALE; MEMBRANE PERMEABILITY; NERVE ENDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

ANIMALS; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUTAMIC ACID; HIPPOCAMPUS; MALE; OMEGA-AGATOXIN IVA; POTASSIUM; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; SYNAPTOSOMES; TETRODOTOXIN; TRITIUM;

EID: 35648948354     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.08.016     Document Type: Article

References (57)

1. Ambrosio A.F., Silva A.P., and Malva J.O. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38 (1999) 1349-1359
2. Angehagen M., Ben-Menachem E., Shank R., Ronnback L., and Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 88 (2004) 320-325
3. Breukel A.I., Besselsen E., Lopes da Silva F.H., and Ghijsen W.E. A presynaptic N-methyl-D-aspartate autoreceptor in rat hippocampus modulating amino acid release from a cytoplasmic pool. Eur. J. Neurosci. 10 (1998) 106-114
4. Brunbech L., and Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 62 (2002) 593-604
5. Calabresi P., De Murtas M., Stefani A., Pisani A., Sancesario G., Mercuri N., and Bernardi G. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 (1995) 990-996
6. Chittajallu R., Vignes M., Dev K.K., Barnes J.M., Collingridge G.L., and Henley J.M. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature 379 (1996) 78-81
7. Errington A.C., Stohr T., and Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr. Top. Med. Chem. 5 (2005) 15-30
8. Galindo C., and Sitges M. Dihydropiridines mechanism of action in striatal isolated nerve endings. Comparison with -agatoxin IVA. Neurochem. Res. 29 (2004) 659-669
9. Galvan E., and Sitges M. Characterization of the participation of sodium channels on the rise in Na+ induced by 4-aminopyridine (4-AP) in synaptosomes. Neurochem. Res. 29 (2004) 347-355
10. Gannon R.L., and Terrian D.M. Presynaptic modulation of glutamate and dynorphin release by excitatory amino acids in the guinea-pig hippocampus. Neuroscience 41 (1991) 401-410
11. Gates J.R. Side effect profiles and behavioral consequences of antiepileptic medications. Epilepsy Behav. 1 (2000) 153-159
12. Hurley L.M., and Graubard K. Pharmacologically and functionally distinct calcium currents of stomatogastric neurons. J. Neurophysiol. 79 (1998) 2070-2081
13. Kelly K.M., Gross R.A., and Macdonald R.L. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci. Lett. 116 (1990) 233-238
14. Kudin A.P., Debska-Vielhaber G., Vielhaber S., Elger C.E., and Kunz W.S. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45 (2004) 1478-1487
15. Kuzmiski J.B., Barr W., Zamponi G.W., and MacVicar B.A. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 46 (2005) 481-489
16. Kwan P., and Brodie M.J. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357 (2001) 216-222
17. Landmark C.J., Rytter E., and Johannessen S.V. Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 16 (2007) 356-364
18. Lees G., and Leach M.J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 612 (1993) 190-199
19. Llinás R., Sugimori N., Hillman D.E., and Cherksey B. Distribution and functional significance of the P-type, voltage-dependent Ca2+ channels in the mammalian central nervous system. Trends Neurosci. 15 (1992) 351-355
20. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs 16 (2002) 669-694
21. Luebke J.I., Dunlap K., and Turner T.J. Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. Neuron 11 (1993) 895-902
22. Margineanu D.G., and Klitgaard H. Caffeine-induced epileptiform field potentials in rat hippocampal slices: a pharmacological characterization. Neuropharmacology 47 (2004) 926-934
23. McLean M.J., and Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237 (1986) 1001-1011
24. Nekrassov V., and Sitges M. Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res. 60 (2004) 63-71
25. Nekrassov V., and Sitges M. Additive effects of antiepileptic drugs and pentylenetetrazole on hearing. Neurosci. Lett. 406 (2006) 276-280
26. Poulsen C.F., Simeone T.A., Maar T.E., Smith-Swintosky W., White H.S., and Schousboe A. Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem. Res. 29 (2004) 275-282
27. Qian J., and Noebels J.L. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res. 55 (2003) 225-233
28. 3H]GABA release. Neurochem. Res. 21 (1996) 889-895
29. Schirrmacher K., Mayer A., Walden J., Dusing R., and Bingmann D. Effects of carbamazepine on action potentials and calcium currents in rat spinal ganglion cells in vitro. Neuropsychobiology 27 (1993) 176-179
30. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. 50 (2002) 21-32
31. Schmidt D., and Elger C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 5 (2004) 627-635
32. Sitges M. Effect of organic and inorganic calcium channel blockers on s-amino-n-butyric acid release induced by monensin and veratrine in the absence of external calcium. J. Neurochem. 53 (1989) 436-441
33. 3H]GABA from synaptosomes. Neurochem. Res. 20 (1995) 1065-1071
34. Sitges M., and Galindo C. Omega-agatoxin-TK is a useful tool to study P-type Ca2+ channel-mediated changes in internal Ca2+ and glutamate release in depolarised brain nerve terminals. Neurochem. Int. 46 (2005) 53-60
35. Sitges M., and Nekrassov V. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem. Res. 24 (1999) 1585-1591
36. Sitges M., and Nekrassov V. Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin. Neurophysiol. 115 (2004) 2711-2717
37. Sitges M., and Nekrassov V. Acute and chronic effects of carbamazepine, phenytoin, valproate and vinpocetine on BAEP parameters and threshold in the guinea pig. Clin. Neurophysiol. 118 (2007) 420-426
38. Sitges M., and Reyes A. Effects of verapamil on the release of different neurotransmitters. J. Neurosci. Res. 40 (1995) 613-621
39. Sitges M., Peña F., Chiu L.M., and Guarneros A. Study on the possible involvement of protein kinases in the modulation of brain presynaptic sodium channels; comparison with calcium channels. Neurochem. Int. 32 (1998) 177-190
40. Sitges M., Nekrassov V., and Guarneros A. Simultaneous action of MK-801 (dizclopine) on dopamine, glutamate, aspartate and GABA release from striatum isolated nerve endings. Brain Res. 854 (2000) 48-56
41. Sitges M., Chiu L.M., and Nekrassov V. Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na(+), Ca(2+) and glutamate release in hippocampal isolated nerve endings. Neurochem. Int. 49 (2006) 55-61
42. Sitges M., Chiu L.M., and Nekrassov V. Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52 (2007) 598-605
43. Stefani A., Pisani A., De Murtas M., Mercuri N., Marciani M.G., and Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36 (1995) 997-1002
44. Stefani A., Spadoni F., Siniscalchi A., and Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur. J. Pharmacol. 307 (1996) 113-116
45. Stefani A., Spadoni F., and Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia 38 (1997) 959-965
46. Taverna S., Mantegazza M., Franceschetti S., and Avanzini G. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res. 32 (1998) 304-308
47. Timmermann D.B., Lund T.M., Belhage B., and Schousboe A. Localization and pharmacological characterization of voltage dependent calcium channels in cultured neocortical neurons. Int. J. Dev. Neurosci. 19 (2001) 1-10
48. Trejo F., Nekrassov V., and Sitges M. Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 909 (2001) 59-67
49. Turner T.J., Adams M.E., and Dunlap K. Calcium channels coupled to glutamate release identified by w-Aga-IVA. Science 258 (1992) 310-313
50. Vermeulen J., and Aldenkamp A.P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res. 22 (1995) 65-95
51. Wang S.J., Huang C.C., Hsu K.S., Tsai J.J., and Gean P.W. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7 (1996) 3037-3040
52. Wang S.J., Shira T.S., and Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12 (2001) 2255-2258
53. Wellington K., and Goa K.L. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS drugs 15 (2001) 137-163
54. Westenbroek R.E., Sakurai T., Elliott E.M., Hell J.W., Starr T.V., Snutch T.P., and Catterall W.A. Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J. Neurosci. 15 (1995) 6403-6418
55. Willow M., Kuenzel E.A., and Catterall W.A. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25 (1984) 228-234
56. Zhang X., Velumian A.A., Jones O.T., and Carlen P.L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41 (2000) S52-S60
57. Zona C., and Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp. Brain. Res. 81 (1990) 313-317